Lipocalin-2 Upregulation in Nasopharyngeal Carcinoma: A Novel Potential Diagnostic Biomarker
Iranian Journal of Medical Sciences · 2023-05 · 48 (3) · 268-276
DOI: 10.30476/ijms.2022.93041.2452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iranian Journal of Medical Sciences, 2023-05. Verfasst von Saghi Jani Kargar Moghaddam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Lipocalin-2 (LCN2) deregulation has been reported in several types of cancer and is implicated in the proliferation, migration, angiogenesis, and progression of tumors. However, its aberrant expression has been rarely studied in nasopharyngeal carcinoma (NPC). In the present study, we investigated the expression of LCN2 in NPC patients.
Methods
In this descriptive cross-sectional study, 29 NPC and 20 non-cancerous control paraffin pathology blocks were obtained from the seven-year (2011 to 2018) archive of Razi Laboratory in Rasht, Iran. LCN2 mRNA expression was evaluated through quantitative real-time PCR. In addition, immunohistochemistry was performed to evaluate LCN2 expression at the protein level. The fold change value and total immunostaining score (TIS) were applied for quantitative evaluation. The nonparametric Mann-Whitney U test and Fisher’s exact test were used through GraphPad Prism 8.3.0 software. P 3) and 34.47% (10/29) as low expression (TIS≤3). While in the control group, 25% (5/20) of subjects represented a high expression of LCN2 (TIS>3), and 75% (15/20) showed no or weak expression (TIS≤3). No significant correlation was found between the overexpression of LCN2 at the protein level and the demographic features of the patients.
Conclusion
Our findings suggest that LCN2 might be considered a potential new diagnostic marker for NPC. However, this warrants further studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran.
- Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
- Otorhinolaryngology Research Center, School of Medicine, Amiralmomenin Hospital, Guilan University of Medical Sciences, Rasht, Iran.
- Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
- Burn and Regenerative Medicine Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Zitieren
APA
Jani Kargar Moghaddam, S., Mohammadi Roushandeh, A., Hamidi, M., Nemati, S., Jahanian-Najafabadi, A., & Habibi Roudkenar, M. (2023). Lipocalin-2 Upregulation in Nasopharyngeal Carcinoma: A Novel Potential Diagnostic Biomarker. Iranian Journal of Medical Sciences, 48(3), 268-276. https://doi.org/10.30476/ijms.2022.93041.2452
Vancouver
Jani Kargar Moghaddam S, Mohammadi Roushandeh A, Hamidi M, Nemati S, Jahanian-Najafabadi A, Habibi Roudkenar M. Lipocalin-2 Upregulation in Nasopharyngeal Carcinoma: A Novel Potential Diagnostic Biomarker. Iranian Journal of Medical Sciences. 2023;48(3):268-276. doi:10.30476/ijms.2022.93041.2452
BibTeX
@article{JaniKargarMoghaddam2023,
author = {Jani Kargar Moghaddam, Saghi and Mohammadi Roushandeh, Amaneh and Hamidi, Masoud and Nemati, Shadman and Jahanian-Najafabadi, Ali and Habibi Roudkenar, Mehryar},
title = {Lipocalin-2 Upregulation in Nasopharyngeal Carcinoma: A Novel Potential Diagnostic Biomarker},
journal = {Iranian Journal of Medical Sciences},
year = {2023},
volume = {48},
number = {3},
pages = {268--276},
doi = {10.30476/ijms.2022.93041.2452}
}
EUVIMED